

Smarter business for a Smarter Planet:

What a predictive model means to a hospital in Africa.

It means that this hospital in Ethiopia will be able to help HIV patients receive the best treatment regimen possible. The EuResist Network is helping doctors predict patient response to multiple HIV treatments with over 78% accuracy. In a recent study, the EuResist prediction engine outperformed 9 out of 10 human experts in choosing the best drug combinations for a range of HIV genetic variants. The tool is built on an IBM analytics solution that integrates over 41,000 HIV treatment histories from a variety of disparate databases onto a flexible IBM DB2[®] platform. A smarter organization is built on smarter software, systems and services.

Let's build a smarter planet. ibm.com/hospital



A data visualization of 41,000 HIV case histories.

The EuResist Network is a research partnership composed of Janssen-Cilag, Hoffmann-La Roche, Bristol-Myers Squibb, Merck, Novartis, AstraZeneca, Sanofi-Schering-Plough, Boehringer-Ingelheim, and others. The EuResist project has been supported by the European Commission. IBM, the IBM logo, ibm.com, DB2, Smarter Planet, and the Smarter Planet logo are trademarks of International Business Machines Corporation. Other product and service names include trademarks of IBM or other companies. A complete list of IBM trademarks is available on the World Wide Web at <http://www.ibm.com/legal/copytrade.shtml>.